Company Filing History:
Years Active: 1993
Title: Innovations in Oncology: The Contributions of Peter T. Dijke
Introduction
Peter T. Dijke is a notable inventor located in Port Washington, NY, recognized for his significant contributions to the field of oncology. His innovative work focuses on methods for obtaining bone marrow free of tumor cells, highlighting the advancements in cancer treatment and diagnostics.
Latest Patents
Peter T. Dijke holds a patent that presents a method for obtaining bone marrow free of tumor cells using transforming growth factor beta-3 (TGF-β3). This patent introduces (1) an antibody that specifically binds to human TGF-β3 without cross-reactivity to TGF-β1 or TGF-β2, and (2) antibodies directed against the pro region of the TGF-β precursor. Additionally, the invention includes a pharmaceutical composition comprising the pro region of the TGF-β precursor, along with methods for diagnosing, detecting, and treating disorders associated with TGF-β3.
Career Highlights
Throughout his career, Dijke has demonstrated a strong commitment to advancing medical science and oncology. His work at Oncogene Science, Inc. has positioned him at the forefront of cancer research, allowing him to develop innovative solutions that address pressing medical challenges. The impact of his patent could lead to significant improvements in patient care and treatment methodologies.
Collaborations
Dijke has collaborated with esteemed colleagues such as Kenneth K. Iwata and J. Gordon Foulkes. These partnerships underscore the importance of teamwork and shared expertise in the pursuit of groundbreaking research and development within the medical field.
Conclusion
Peter T. Dijke's contributions to cancer research, particularly through his patented methods for obtaining tumor-free bone marrow, represent significant milestones in the fight against cancer. His innovative approach not only showcases the potential for better diagnostic and treatment options but also highlights the critical role of inventors in the advancement of medical science. With ongoing collaboration and research, the implications of his work may continue to reshape oncology for years to come.